Goal and Learning Outcomes

At the conclusion of this activity, you should be better prepared to:

  • Review the pathophysiology of SSc-ILD and the implications that new insights have for diagnosing and treating the disease
  • Recognize key risk factors and diagnostic tests that could improve early symptom recognition and prognosis of the disease.
  • Evaluate key data on new and emerging treatment options for SSc-ILD to properly educate patients.
  • Implement team-based strategies to improve individualization of treatment plans for patients with SSc-ILD.



Steven Nathan, MD

Medical Director, Advanced Lung Disease and Lung Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Kristin Highland, MD, MSCR

Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Justin Oldham, MD, MS

Assistant Professor of Medicine
Director, Interstitial Lung Disease Program
University of California, Davis
Davis, CA

Joshua Solomon, MD

Associate Professor of Medicine
Autoimmune Lung Center and Interstitial Lung Disease Program
National Jewish Health
Denver, CO

Accreditation Information

This course is being provided by a Relias LLC strategic partner.  Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.